This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
None.
References
Copland E, Canoy D, Nazarzadeh M, Bidel Z, Ramakrishnan R, Woodward M, et al. Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol. 2021;22:558–70.
Berrido AM, Byrd JB. Angiotensin receptor blockers and the risk of cancer: insights from clinical trials and recent drug recalls. Curr Hypertens Rep. 2020;22:20.
Wu Z, Yao T, Wang Z, Liu B, Wu N, Lu M, et al. Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis. Br J Cancer. 2023;128:168–176.
Almutlaq M, Alamro AA, Alamri HS, Alghamdi AA, Barhoumi T. The effect of local renin angiotensin system in the common types of cancer. Front Endocrinol. 2021;12:736361.
Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI Paradox. Circulation. 2017;135:2088–90.
Franklin JM, Patorno E, Desai RJ, Glynn RJ, Martin D, Quinto K, et al. Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative. Circulation. 2021;143:1002–13.
Helgeson SA, Waddle MR, Burnside RC, Debella YT, Lee AS, Burger CD, et al. Association between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and lung cancer. South Med J. 2021;114:607–13.
Sipahi I, Chou J, Mishra P, Debanne SM, Simon DI, Fang JC. Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. Am J Cardiol. 2011;108:294–301.
Collaboration ARBT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29:623–35.
Sipahi I. Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: meta-regression analysis of randomized trials. PLoS ONE. 2022;17:e0263461.
Levy BI, Mourad JJ. Renin Angiotensin blockers and cardiac protection: from basis to clinical trials. Am J Hypertens. 2022;35:293–302.
Funding
None.
Author information
Authors and Affiliations
Author notes
Unaffiliated.
- Ilke Sipahi
Contributions
All authors equally contributed.
Corresponding author
Ethics declarations
Competing interests
Dr. ASH has received lecture honoraria from Servier a manufacturer of an ACE inhibitor. Dr. MHS has received honoraria for lecture honoraria and advisory boards from Servier a manufacturer of an ACE inhibitor. Dr. IS has received lecture honoraria from Novartis, Boehringer-Ingelheim, Sanofi, Sandoz, Bristol-Myers Squibb, Bayer, Pfizer, Ranbaxy, Servier and ARIS and served on advisory board for Novartis, Sanofi, Servier, Bristol-Myers Squibb, Pfizer, Bayer and I.E. Ulagay some of which manufacture ACE inhibitors or ARB.
Ethics approval and consent to participate
Not applicable.
Consent for publication
All authors consent, the figure included is copyrighted by Dr. IS and was previously published.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Strauss, M.H., Sipahi, I. & Hall, A.S. ACE inhibitors and the risk of lung cancer—is there causality?. Br J Cancer 129, 570–571 (2023). https://doi.org/10.1038/s41416-023-02346-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-023-02346-3